--- title: "TransCode Therapeutics (RNAZ.US) — Financial Reports" type: "Symbol" locale: "en" url: "https://longbridge.com/en/quote/RNAZ.US/norm.md" symbol: "RNAZ.US" name: "TransCode Therapeutics" parent: "https://longbridge.com/en/quote/RNAZ.US.md" datetime: "2026-06-13T21:01:55.769Z" locales: - [en](https://longbridge.com/en/quote/RNAZ.US/norm.md) - [zh-CN](https://longbridge.com/zh-CN/quote/RNAZ.US/norm.md) - [zh-HK](https://longbridge.com/zh-HK/quote/RNAZ.US/norm.md) --- # TransCode Therapeutics (RNAZ.US) — Financial Reports ## Income Statement (USD) | Indicator | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | | --- | --- | --- | --- | --- | --- | | EPS | -21.28 | -16.49 | -5.82 | -5.13 | -70.16 | | ROE | -1347.07% | -1023.91% | -512.94% | -208.10% | -1168.52% | | Revenue | - | - | - | - | - | | Net income | -19.51M | -15.05M | -4.86M | -4.28M | -12.09M | | Operating income | -7.33M | -7.24M | -4.56M | -4.22M | -3.17M | | Gross margin | - | - | - | - | - | | Net margin | - | - | - | - | - | | Profit quality | - | - | - | - | - | ## Balance Sheet (USD) | Indicator | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | | --- | --- | --- | --- | --- | --- | | A&L | 157.16M | 162.40M | 5.23M | 8.27M | 13.19M | | Leverage | 1.09 | 1.07 | 3.67 | 1.34 | 1.28 | | BVPS | 1.36 | 11.27 | 1.71 | 7.37 | 12.35 | | Turnover | - | - | - | - | - | | Cash & STI | 12.84M | 17.81M | 2.84M | 7.37M | 11.57M | | Inv & Rec | - | - | - | - | - | | LT assets | 346745.00 | 370681.00 | 19908.00 | 24689.00 | 38131.00 | | Net debt | -12.84M | -17.81M | -2.84M | -7.37M | -11.57M | ## Cash Flow Statement (USD) | Indicator | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | | --- | --- | --- | --- | --- | --- | | Operating CF | -4.98M | -8.14M | -4.08M | -4.19M | -3.10M | | Investing CF | - | -4436.00 | - | - | - | | Financing CF | - | 23.12M | -455726.00 | 0.0000 | 8.85M | | Free CF | -2.42M | -6.15M | -2.36M | -2.83M | -2.19M | | OCF coverage | - | -122252.40% | - | - | - | | Repaid & issued | - | - | - | - | - | | CapEx | - | -6660.00 | - | - | - |